

Changes in Serum Estradiol Levels and Histomorphological Evaluation of Cortical Thickness in Long Bones of Mice Induced by Anastrozole and Protective Effect of Olive Oil

Anjum Ishaq¹, Munir Hussain², Saima Nadeem³, Shagufta Nasir⁴, Khalid Javed⁵ and Arshad Parvez⁶
^{1, 2, 3, 4, 5}Department of Pathology Khyber Girls Medical College, ⁶Department of Pathology North West School of Medicine

ABSTRACT

Background: Breast cancer is the second major cause of death among women worldwide. Drugs like anastrozole are effective standardized therapy for postmenopausal breast cancer patients. Anastrozole causes estrogen deficiency by inhibiting enzyme Aromatase. Estrogen has an important dynamic role in growth as well as development of bone, both in men and women. Olive oil can be used as non-hormonal therapy to improve skeletal health by maintaining bone mineral density in patients taking anastrozole.

Objective: The aim of this study was to find out protective effect of olive oil in bone loss induced by the use of anastrozole.

Materials and Methods: Sixty female albino mice, 6-8 weeks of age were used in this experimental study. Aromatase inhibitor drug anastrozole was given alone and in combination with olive oil once daily for 30 consecutive days. Mice were divided into three groups. Group 1 (Control group) which were given normal diet only, Group 2 (Drugged mice group) and Group 3 (Drugged + Olive oil group). Blood samples were taken by cardiac puncture and ECLIA method was used for serum estradiol estimation. Femur bone specimens were obtained and examined for histomorphological evaluation of cortical thickness. Study duration was from March - December 2019.

Results: Different parameters of all the groups were measured before and after experiment. After experiment, group 1 mice showed increased levels of serum estradiol (18.25 ± 5.01 pg/ml), as compared to group 2 (9.21 ± 2.12 pg/ml) and group 3 mice (14.79 ± 2.53 pg/ml). Group 1 mice had femur weight of 0.08 ± 0.01 grams as compared to group 2 (0.05 ± 0.006 grams) and group 3 mice (0.07 ± 0.008 grams). Mean cortical thickness of group 1 mice was (273.00 ± 15.67 μ m), that of group 2 was (138.00 ± 19.89 μ m), and that of group 3 mice was (189.50 ± 14.31 μ m).

Conclusion: The results showed beneficial and protective effects of olive oil in anastrozole induced bone loss in female albino mice.

Key Words: breast cancer, estrogens, aromatase inhibitor, osteoporosis, olive oil.

Introduction

Cancer is one of main causes of mortality worldwide. As population grows the overall number of cases of cancer and mortality increases¹. Regardless of the improvements in cancer treatments, it is still the prominent and the most important cause of death in the world^{2,3}. It is considered 2nd commonly detected cause of female mortality^{4,5,6}.

In 2012, an approximately, 1700,000 (1.7 million) cases and over half a million (521,900) mortalities occurred worldwide from breast cancer⁷⁻⁸. Higher incidence is predicted in higher income groups^{9,10,11}.

Throughout Pakistan, the breast cancer is one of the most dominant and commonly diagnosed cause of malignancy in females. In 2012, estimated 5-year incidence of the disease in Pakistan was 119,710 cases including 34,038 new identified cases and 16,232 deaths^{12,13}. In the United States, in 2012, above 200,000 women were detected having carcinoma breast. In the United States, therefore, it is crucial to monitor the long term consequences especially bone health of successfully treated breast cancer patients¹⁴.

CORRESPONDENCE AUTHOR

Dr. Munir Hussain

Department of Pathology
Khyber Girls Medical College Hayatabad

Email: sendtodrmunir@gmail.com

Breast cancer treatment and prognosis options are usually based on staging, vascular and lymphatic spread, histological grade, presence or absence of hormone receptors, ERBB2 over expression and concomitant diseases. Patient's age and status of menopause are also important factors regarding treatment.

Nearly 70% of breast tumours have hormonereceptors (oestrogen or progesterone), therefore in order to reduce the risk of relapse, anti-hormonal treatments are frequently used. Anti-hormonal and chemotherapeutic agents can induce osteoporotic changes and thus have a destructive effect on bone health. Hence, in such patients, the bone health management is a key factor for care and survival¹⁵.

Osteoporosis is a "silent" disorder as there is usually no distinct threatening or alarming signs, till a fracture occurs. The overall yearly incidence of osteoporotic fractures is higher compared to carcinoma breast, cardiac arrest and stroke combined.

Aromatase inhibitors are endocrine drugs used in breast cancer and they exert their action by blocking the production of oestrogen¹⁵. Anastrozole is an effective and potent non-steroidal aromatase inhibitor. Aromatase inhibitors block the enzyme Aromatase which catalyzes a key aromatization step in the synthesis of estrogen. They are largely used in post-menopausal patients having hormone receptor positive (estrogen receptor) cancer^{16,17,18}. They are associated with severe loss of bone and fractures¹⁹. Olive oil and its phenolic compounds, both in vivo and in vitro have antioxidant properties^{20,21}. The consumption of phenols may prevent bone cells damage caused by oxidation and has positive impact on bone mineral density.

Objectives

The study aimed to observe the protective effect of olive oil in bone loss secondary to decreased estradiol levels after anastrozole administration.

Materials and Methods

The study was approved by the ASRB (Advanced Study and Research Board, DIR/ KMU AS&RB/EM/000892) and the Khyber Girls Medical College Ethical Board, after approval by the Graduate Study Committee (GSC) of Khyber Girls Medical College.

It was an analytical experimental study conducted from March 2019 to December 2019. The study was carried out in animal house of "Pakistan Council for

Scientific and Industrial Research (PCSIR), and Pathology department of KGMC, Peshawar. A total of 60 female albino mice were included in this study. Only non-pregnant mice, 6-8 weeks of age were included, while male albino mice were excluded from the study. Non probability consecutive sampling technique was used. Sixty mice were segregated into 3 groups. In group 1 (control group) there were total of 10 mice. They were on routine standard diet only. In group 2 (drugged group) there were 25 mice and were on drug anastrozole, to whom dose of 0.1mg/kg bodyweight was given once daily. In group 3 (drugged + Olive group) there were 25 mice and they were given 1ml olive oil daily along with 0.1mg/kg/per day of anastrozole.

Blood was collected by cardiac puncture for estrogen estimation. Estrogen estimation was done by Enhanced "Chemiluminescence" Immunoassay (ECLIA). ECLIA is an immunoassay which uses electrochemical compounds to generate. The test was performed on Cobaselecsys e411 analyzer by ROCHE diagnostics. Femur bone was collected for histomorphological evaluation of cortical thickness. The standard ocular graticule and stage micrometer were used to measure the cortical thickness of the femur bones, of all experimental albino mice.

Ocular or eye-piece graticule/reticule is a glass disc, placed in the eye-piece of the microscope. It is 10mm long with regular 100 sub-divisions, called ocular units (o.u). The engraved side of the ocular graticule faces downward. Eye-piece graticule divisions are arbitrary and need to be calibrated for each power, because it shows different values for same object depending on magnification used. For this purpose, stage micrometer is used with calibrated known measurement. In this project, calibration was done for low power i.e. 10X. Stage micrometer is (1 x 3 cm) glass slide or glass ruler placed on the stage of the microscope. The length of the stage micrometer is 10mm with 100 divisions. Therefore,

100 divisions = 10mm or

1 stage units (s.u) = 1/10 = 0.1mm

1mm = 1000 μ m and

0.1mm = 100 μ m therefore, 1 stage unit = 100 μ m

At 10X, standard measurement of ocular graticule = 100 divisions

10 o.u = 1 stage unit = 100 μ m

Therefore 1 ocular unit = 100/10 = 10 μ m

Slide microscopy was done for measurement of cortical thickness.




Figure: 1: Calibration of ocular graticule and stage micrometer at 10x magnification

Data was analysed using SPSS version 23. Means and standard deviations were calculated for continuous data like weight, length of femur bone, estradiol levels and cortical thickness of femur bone. The means of different variables like estradiol levels, femur length, femur weight and mean cortical thickness of all three groups were compared by applying one way anova. A level of $\leq .05$ at 95% confidence interval was taken as significant.

Results

The study results showed that anastrozole given alone caused significant reduction in serum estradiol levels and considerable loss of cortical thickness of femur bone (osteoporotic changes). The extent of damage was observed by gross parameters like weight of mice, length, weight, color and texture of femur bone. The results of group 2 and 3 were compared with group 1 i.e. control group given normal, standard diet and tap water. Comparison of group 2 and group 3 was also done. Group 3 treated with olive oil revealed less adverse effects in bones as matched with anastrozole treated group 2 having worst adverse impact on bones.

Table 3: Mean cortical thickness and weight of femur of all experimental groups

| Femur cortical thickness (μm) | Groups | Mean | SD | Sig | Mean femur bone weight (Grams) | Mean | SD | Sig |
|---|------------------------------------|--------|--------|---------|--------------------------------|---------|---------|------|
| | Control (10) and Drugged mice (20) | | 273.00 | 15.67 | | <0.001# | 0.08 | 0.01 |
| | | 138.00 | 19.89 | | | | | |
| Control (10) and Drug and olive oil (20) | | 273.00 | 15.67 | <0.001# | 0.08 | 0.01 | 0.001# | |
| | | 189.50 | 14.31 | | | | | |
| Drugged mice (20) and Drug and Olive oil (20) | | 138.00 | 19.89 | <0.001# | 0.05 | 0.006 | <0.001# | |
| | | 189.50 | 14.31 | | | | | |

#: One way anova, N: Number, SD: Standard deviation, Sig: Significance level

Table 1: Mean serum estradiol levels (pg/ml) of all mice groups.

| Groups | Mean | Std. Deviation | Sig |
|---|-------|----------------|--------|
| Control (10) and Drugged mice (20) | 18.25 | 5.01 | <.001# |
| | 9.21 | 2.12 | |
| Control (10) and Drug and Olive oil(20) | 18.25 | 5.01 | <.014# |
| | 14.79 | 2.53 | |
| Drugged mice (20) and Drug and Olive oil (20) | 9.21 | 2.12 | <.001# |
| | 14.79 | 2.53 | |

#: One way anova, Sig: Significance level

There was a highly significant difference of serum estradiol levels among all the groups. On comparison, there was significant difference ($<.001$) between the group 1 (control group) and group 2 (drugged group) and same difference between group 2 (drugged group) and 3 (drugged + olive oil group). While the significance level between group 1 (control group) and 3 (drugged + olive oil group) was $<.014$.

Table 2: Mean femur bone length of all mice groups.

| Groups | Mean | SD | Sig |
|---|------|-------|--------|
| Control (10) and Drugged mice (20) | 1.57 | 0.050 | 0.04# |
| | 1.52 | 0.040 | |
| Control (10) and Drug and Olive oil(20) | 1.57 | 0.050 | 0.005# |
| | 1.50 | 0.062 | |
| Drugged mice (20) and Drug and Olive oil (20) | 1.52 | 0.040 | 0.62# |
| | 1.50 | 0.062 | |

One way anova, SD: Standard deviation, Sig: Significance level

There was significant difference of 0.04 between the mean femur lengths of group 1 and group 2 and a highly significant difference of 0.005 between group 1 and 3 but there was no significant difference (0.62) between group 2 and 3.

Mean cortical thickness of femur was greatest in group 1 (control group) while in group 2 (drugged group) it was least of all. On the contrary in group 3 (drugged + olive oil group) it was greater than group 2, though lesser than control group. The mean femur weight of group 1 was greatest of all. Among treated groups the mean weight of group 3 was more than that of group 2.



Figure 2A: Cortical thickness of control group




Figure 2B: Cortical thickness of group 2




Figure 2C: Cortical thickness of group 3

Discussion

This study was conducted to evaluate the impact of the anticancer drug anastrozole on bones, commonly prescribed in postmenopausal, hormone sensitive (HR+) breast cancer patients. Moreover, study aimed at evaluation of efficacy and effectiveness of olive oil on bone mineral density (BMD) in those mice which received anastrozole.

The study results were supportive of protective role of olive oil against bone damages caused by osteoporosis in general. This research showed considerable loss of weight of mice and femur bone in group 2 which was treated with anastrozole. This finding was consistent with the study conducted by Gaillard et al.²², which showed loss of weight, bone pains, osteoporosis and increased risk of fracture. Another study, ATAC trial (median follow-up, 68 months) conducted by Richard Eastell et al, showed increase bone loss associated with 5 years therapy with anastrozole²³. In ATAC trial study, fracture rates were higher in groups treated with anastrozole (2.93%) as compared to tamoxifen (1.9%), with a highly statistically significant difference of <0.0001. The same fact was observed in another study conducted by Amr a Rezaq et al. in 2010, showing that, the bone mineral contents were improved by dietary intake of olive oil²⁴. Olive oil increases the calcium and phosphorus in bone and decreases the urinary calcium excretion in mice.

Our study showed marked reduction in cortical thickness of the femur bone of mice treated with Anastrozole (group 2) as compared to control group (group 1) and olive oil treated group (group 3). The same findings were also found in a study conducted by FIMarcu et al.²⁵, in which, 47 bone tissue samples were collected. Twenty seven bone samples were collected from femoral head and 20 were collected

from the vertebral body of 60-70 years old dead patients. The results showed marked thinning in trabecular bone. On the other hand, mice treated with olive oil along with anastrozole (group 3) showed marked improvement in cortical thickness, proving efficacy and effectiveness of olive oil regarding bone health management in breast cancer patients receiving aromatase inhibitors like anastrozole. This effect of olive oil was also documented by another trial, conducted to estimate the protective role of olive oil against osteoporosis in ovariectomized rats²⁶. Our experimental trial showed marked reduction in serum estradiol level in anastrozole treated group. Same results were also reflected in Folkerdet al and Jamal Zidan et al studies^{27, 28}. Group 3 mice treated with olive oil showed improved serum estradiol levels as compared to group 2, showing that olive oil has beneficial role regarding bone density by improving estrogen level. Studies support that dietary intake of olive oil plays an important role in improving bone health due to its anti-oxidative and anti-inflammatory properties²⁹.

Conclusion

Our experimental trial concluded that, aromatase inhibitor drug anastrozole caused marked reduction of serum estrogen levels in the female albino mice which led to decreased length, weight and cortical thickness of femur bones. The study also showed protective effects of olive oil on bone health by increasing estrogen levels and thereby improving different bone parameters including cortical thickness and weight. This protective effect of olive oil is helpful in reducing the risk of future fractures.

Recommendations

It is recommended that olive oil should be made a part of diet in general and especially in patients treated with aromatase inhibitors.

Conflict of Interest

Authors bear no conflict of interest.

References

1. Torre LA, Siegel RL, Ward EM, Jemal AJ. Cancer, biomarkers, prevention. Global Cancer Incidence and Mortality Rates and Trends – An Update. *Global Cancer Rates and Trends – An Update*. 2016;25(1):16-27. doi: 10.1158/1055-9965.
2. Hoskin P, Neal AJ, Hoskin PJ. Clinical oncology: Basic principles and practice: 4th ed. USA. CRC Press; 2009. Chapter 10, Breast Cancer; p. 89.
3. Hoskin P, Neal AJ. Clinical Oncology: Basic Principles and Practice: 3rd ed. Hodder Education Group, London; 2003. CNS tumours. p.161
4. Mulryan C. Understanding cancer: the basics. *BJHCA*. 2010;4(6):266-9. doi:10.12968/bjha.2010.4.6.48484
5. Fallon M, Hanks G. ABC of palliative care: 2nd ed. Massachusetts. Blackwell Publishing Ltd; 2006.
6. Rosa M. Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine. *Cancer Control*. 2015 Apr; 22(2):211-9. doi: 10.1177/107327481502200213.
7. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015 Mar 1; 136(5):E359-86. doi: 10.1002/ijc.29210.
8. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. *APJCP*. 2016; 17(S3):43-6. doi:10.7314/apjcp.2016.17.s3.43
9. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA: a cancer journal for clinicians*. 2017; 67(2):100-21. doi:10.3322/caac.21392.
10. Screening P, Board PE. Breast Cancer Screening (PDQ®). PDQ Cancer Information Summaries: USA. National Cancer Institute; 2022.
11. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: IARC; 2013.
12. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2016;25(1):16-27. doi:10.1158/1055-9965.Epi-15-0578
13. Sarwar MR, Saqib A. Cancer prevalence, incidence and mortality rates in Pakistan in 2012. *Cogent Medicine* 2017;4(1).doi:10.1080/2331205X.2017.1288773
14. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. *CA: a cancer journal for clinicians*. 2012;62(4):220-41. doi:10.3322/caac.21149
15. Boutas I, Pergialiotis V, Salakos N, Agrogiannis G, Konstantopoulos P, Korou LM, et al. The impact of Anastrozole and Letrozole on the metabolic profile in an experimental animal model. *Scientific reports*. 2015;5:17493. doi:10.1038/srep17493
16. Stuber J, Dieterich M, Gerber B. Medical prevention of breast cancer. *Breast care (Basel)*. 2014;9(6):391-6. doi: 10.1159/000369573

17. Egbuta C, Lo J, Ghosh D. Mechanism of inhibition of estrogen biosynthesis by azole fungicides. *Endocrinology*. 2014; 155(12):4622-8. doi: 10.1210/en.2014-1561.
18. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. *J ClinOncol*. 2016; 34(14):1689-701. doi: 10.1200/JCO.2015.65.9573.
19. Lønning PE, Geisler Jr, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. *J ClinOncol*. 2005; 23(22):5126-37. doi: 10.1200/JCO.2005.07.097.
20. Cicerale S, Lucas L, Keast R. Antimicrobial, antioxidant and anti-inflammatory phenolic activities in extra virgin olive oil. *Current opinion in biotechnology*. 2012; 23(2):129-35. doi: 10.1016/j.copbio.2011.09.006.
21. Oliveras-López M-J, Molina JJM, Mir MV, Rey EF, Martín F, de la Serrana HL-G. Extra virgin olive oil (EVOO) consumption and antioxidant status in healthy institutionalized elderly humans. *Arch GerontolGeriatr*. 2013;57(2):234-42. doi: 10.1016/j.archger.2013.04.002.
22. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. *Breast cancer research: BCR*. 2011; 13(2):205. doi. 0.1186/bcr2818: 10.1186/bcr2818
23. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. *J ClinOncol* : 2008;26(7):1051-7. doi.10.1200/jco.2007.11.0726
24. Rezaq AA, Labib FA, Attia AEM. Effect of some dietary oils and fats on serum lipid profile, calcium absorption and bone mineralization in mice. *Pak J Nutr*2010;9(7):643-50. doi.10.3923/pjn.2010.643.650
25. Marcu F, Bogdan F, Muțiu G, Lazăr L. The histopathological study of osteoporosis. *Rom J MorpholEmbryol*. 2011;52(1 Suppl):321-5. <https://pubmed.ncbi.nlm.nih.gov/21424070/>
26. Saleh NK, Saleh HA. Olive oil effectively mitigates ovariectomy-induced osteoporosis in rats. *BMC complementary and alternative medicine*.2011;11:10. doi.10.1186/1472-6882-11-1031.
27. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. *J ClinOncol*: 2012;30(24):2977-80. doi.10.1200/jco.2012.42.0273:
28. Zidan J, Chetver L, Hussein O, Zucker MJTO. Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer. *Oncologist*.2010;15(11):1159-63. doi: 10.1634/theoncologist.2009-0222
29. Escrich E, Moral R, Grau L, Costa I, Solanas M. Molecular mechanisms of the effects of olive oil and other dietary lipids on cancer. *Molecular nutrition & food research*. 2007;51(10):1279-92. doi.10.1002/mnfr.200700213

| HISTORY | |
|-----------------------------------|------------|
| Date received: | 13-9-2022 |
| Date sent for review: | 16-9-2022 |
| Date received reviewers comments: | 26-9-2022 |
| Date received revised manuscript: | 18-10-2022 |
| Date accepted: | 5-12-2022 |

| CONTRIBUTION OF AUTHORS | |
|--------------------------------|---------------------|
| Author | Contribution |
| AnjumIshaq | A,B |
| Munir Hussain | A,C |
| SaimaNadeem | A |
| Shagufta Nasir | C |
| Khalid Javed | A |
| Arshad Parvez | C |

KEY FOR CONTRIBUTION OF AUTHORS:

- A. Conception/Study designing/Planning
- B. Active Participation in Active Methodology
- C. Interpretation/ Analysis and Discussion